Investigating brain function in hereditary Parkinson-dystonia syndromes
SensoMo-PD: Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes
This study is trying to see how the brains of people with hereditary Parkinson-dystonia syndromes work differently, whether they have symptoms or not, by testing them in their own homes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Hospital Schleswig-Holstein Academic / other |
| Locations | 1 site (Lübeck, Schleswig-Holstein) |
| Trial ID | NCT05713721 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore how the brain communicates in individuals with hereditary Parkinson-dystonia syndromes, focusing on mutation carriers who may or may not exhibit symptoms. Researchers will utilize a mobile examination unit to assess participants in their homes, employing techniques such as transcranial magnetic stimulation and video-based clinical examinations. The goal is to identify neurophysiological differences between symptomatic and asymptomatic carriers of specific genetic variants, enhancing our understanding of these rare conditions.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years with pathogenic variants in the Parkin, PINK1, GCH1, or TAF1 genes, as well as healthy controls without movement disorders.
Not a fit: Patients under 18 years, pregnant individuals, those with epilepsy, or those on medications affecting the central nervous system may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and early detection of Parkinson-dystonia syndromes, potentially guiding future therapeutic strategies.
How similar studies have performed: Previous studies have indicated distinct neurophysiological patterns in different Parkinson-dystonia syndromes, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria for mutation carriers: * Pathogenic Parkin, PINK1, GCH1, or TAF1 gene variant * Age \>18 years * Informed consent Inclusion criteria for healthy control participants: * No movement disorder * Age \>18 years * Informed consent * No medication with influences on the central nervous system Exclusion Criteria: * Age \<18 years * Pregnancy * Epilepsy * Medication that reduces the seizure threshold
Where this trial is running
Lübeck, Schleswig-Holstein
- Institute of Systems Motor Science Lübeck — Lübeck, Schleswig-Holstein, Germany (Recruiting)
Study contacts
- Principal investigator: Anne Weissbach, MD — Institute of Systems Motor Science
- Study coordinator: Anne Weissbach, MD
- Email: anne.weissbach@neuro.uni-luebeck.de
- Phone: +49 451 3101 8219
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.